DR. DATSONS LABS | NATCO PHARMA | DR. DATSONS LABS/ NATCO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | 34.4 | - | View Chart |
P/BV | x | 0.2 | 4.9 | 3.3% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
NATCO PHARMA Mar-19 |
DR. DATSONS LABS/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 849 | 14.8% | |
Low | Rs | 31 | 557 | 5.5% | |
Sales per share (Unadj.) | Rs | 133.0 | 573.8 | 23.2% | |
Earnings per share (Unadj.) | Rs | 0.2 | 176.0 | 0.1% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 198.2 | 3.3% | |
Dividends per share (Unadj.) | Rs | 0 | 6.25 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 842.7 | 15.3% | |
Shares outstanding (eoy) | m | 31.66 | 36.50 | 86.7% | |
Bonus/Rights/Conversions | FCCB | BB | - | ||
Price / Sales ratio | x | 0.6 | 1.2 | 48.0% | |
Avg P/E ratio | x | 516.1 | 4.0 | 12,921.5% | |
P/CF ratio (eoy) | x | 11.8 | 3.5 | 333.9% | |
Price / Book Value ratio | x | 0.6 | 0.8 | 72.8% | |
Dividend payout | % | 0 | 3.6 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 25,660 | 9.7% | |
No. of employees | `000 | NA | 5.0 | 0.0% | |
Total wages/salary | Rs m | 56 | 3,559 | 1.6% | |
Avg. sales/employee | Rs Th | NM | 4,225.3 | - | |
Avg. wages/employee | Rs Th | NM | 718.0 | - | |
Avg. net profit/employee | Rs Th | NM | 1,295.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 20,945 | 20.1% | |
Other income | Rs m | 79 | 1,302 | 6.0% | |
Total revenues | Rs m | 4,289 | 22,247 | 19.3% | |
Gross profit | Rs m | 569 | 7,948 | 7.2% | |
Depreciation | Rs m | 204 | 810 | 25.2% | |
Interest | Rs m | 430 | 193 | 222.9% | |
Profit before tax | Rs m | 13 | 8,247 | 0.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6 | 1,823 | 0.3% | |
Profit after tax | Rs m | 5 | 6,424 | 0.1% | |
Gross profit margin | % | 13.5 | 37.9 | 35.6% | |
Effective tax rate | % | 48.0 | 22.1 | 217.3% | |
Net profit margin | % | 0.1 | 30.7 | 0.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 23,472 | 29.2% | |
Current liabilities | Rs m | 6,711 | 7,287 | 92.1% | |
Net working cap to sales | % | 3.3 | 77.3 | 4.3% | |
Current ratio | x | 1.0 | 3.2 | 31.7% | |
Inventory Days | Days | 161 | 92 | 174.5% | |
Debtors Days | Days | 318 | 88 | 361.0% | |
Net fixed assets | Rs m | 3,673 | 18,648 | 19.7% | |
Share capital | Rs m | 317 | 365 | 86.7% | |
"Free" reserves | Rs m | 3,761 | 34,525 | 10.9% | |
Net worth | Rs m | 4,078 | 30,760 | 13.3% | |
Long term debt | Rs m | 1,671 | 0 | - | |
Total assets | Rs m | 12,633 | 43,031 | 29.4% | |
Interest coverage | x | 1.0 | 43.7 | 2.4% | |
Debt to equity ratio | x | 0.4 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.5 | 68.5% | |
Return on assets | % | 3.4 | 15.4 | 22.4% | |
Return on equity | % | 0.1 | 20.9 | 0.6% | |
Return on capital | % | 7.7 | 27.4 | 28.0% | |
Exports to sales | % | 22.9 | 0 | - | |
Imports to sales | % | 14.3 | 0 | - | |
Exports (fob) | Rs m | 964 | NA | - | |
Imports (cif) | Rs m | 602 | NA | - | |
Fx inflow | Rs m | 964 | 11,536 | 8.4% | |
Fx outflow | Rs m | 607 | 2,939 | 20.7% | |
Net fx | Rs m | 357 | 8,597 | 4.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 6,688 | 20.1% | |
From Investments | Rs m | -2,256 | -6,122 | 36.8% | |
From Financial Activity | Rs m | -1,200 | -509 | 235.7% | |
Net Cashflow | Rs m | -2,111 | 66 | -3,198.0% |
Indian Promoters | % | 4.5 | 52.0 | 8.7% | |
Foreign collaborators | % | 0.0 | 1.5 | - | |
Indian inst/Mut Fund | % | 0.0 | 7.8 | - | |
FIIs | % | 1.4 | 16.6 | 8.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 26.0 | 361.9% | |
Shareholders | 20,807 | 25,395 | 81.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. DATSONS LABS With: ALEMBIC PHARMA DISHMAN PHARMA J.B.CHEMICALS TORRENT PHARMA BIOCON
Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
Should you subscribe to the IPO of MSPC Limited?
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More